Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Stock Information for Minerva Neurosciences Inc
Loading
Please wait while we load your information from QuoteMedia.